Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
The focus is to build collaborative learning and sharing ecosystem
The new solution, built on patented blockchain technology, dynamically adapts to patients' behaviour patterns to make clinical encounters more effective
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
He was earlier associated with leading industry players like Hindustan Unilever, TATA Communications, Dr. Lal Path Labs, Oncquest and Metropolis Healthcare
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
